Bharat Biotech plans to boost production of its COVID-19 vaccine, Covaxin, to 12 million doses per month by July, form the present 5 million.
The Hyderabad-based company has made preparations to start bulk production at its Bengaluru facility, The Economic Times reported.
“The company possesses the test licence to start out production of Covaxin in Bengaluru. The fill-finish lines of its existing Hyderabad facility are going to be used before the vaccine is shipped to the Central Drug Laboratory (CDL) for final approval,” a government official told the paper.
The second wave of COVID-19 cases in India has created an urgent need for more doses of Covaxin and therefore the Oxford-AstraZeneca vaccine (Covishield), and emergency approvals of more vaccines.
Maharashtra CM Uddhav Thackeray signs off on lockdown; meeting with task force on 11 April
Bharat Biotech has had discussions regarding tie-ups with other companies to spice up manufacturing of shots, The Economic Times reported.
“The demand for Covaxin has gone up manifold and hence there’s a requirement to build up production. The technology are often transferred to those companies which are BSL (bio safety level) III or have an interest in upgrading their facility,” a source told the paper.
Bharat Biotech asks for Rs 15 crore in finance— The report states that its facilities in Hyderabad and Bengaluru cost Rs 75 crore.
As of seven am on April 12, 10.45 crore doses of COVID-19 vaccines are administered, consistent with the Union health ministry.